Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 research study open to eligible people
Anti-NMDA receptor encephalitis is a disorder where the immune system mistakenly attacks the brain. UCSF is researching the potential of Satralizumab to treat people with this disorder. The clinical trial examines safety, effectiveness, and the interaction between the drug and the body.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for Anti-NMDA Receptor Encephalitis research studies include Jeffrey Gelfand.
Last updated: